SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI), announced today that Health Canada has granted marketing approval for Vitaros® as a first-line therapy for erectile dysfunction. Vitaros® is Apricus Bio’s proprietary, topically-applied, on-demand treatment for erectile dysfunction.
